CSF2 and melanoma: In vitro responses of melanoma cells to GM-CSF may be developed to a predictive biomarker to better assess the response of individual melanoma patients to GM-CSF treatment thereby providing a tool to segregate melanoma patients who will benefit from GM-CSF therapy from those who will not.